# Michael Yi > Michael Yi is a Series B investor at Hillhouse Investment backing Biotechnology and Health Care. See 23 investments, check sizes, portfolio. Updated Aug 2026. - Type: Angel Investor - Fund: [Hillhouse Investment](https://shizune.co/investors/profile/hillhouse-investment) - Location: Beijing, China - Total investments: 23 - Last investment: Aug 2021 - Lead investor: 70% - Last updated: Aug 2026 - LinkedIn: https://www.linkedin.com/in/michael-y-7b08238/ - Website: https://18salisbury.capital Michael Yi is a Series B investor at Hillhouse Investment in Beijing focused on Biotechnology and Health Care. Mr. YI leads Hillhouse Capital’s healthcare investment and has made investments into Wuxi AppTec, Ganlee, BeiGene, Innovent and Junshi, in addition to establishing a China JV with Mayo Clinic-Huimei Healthcare. He holds an MBA from the Marshall School of Business at University of Southern California. ## Investment focus ### Industry | Industry | Investments | Share | | --- | --- | --- | | Biotechnology | 7 | 30% | | Health Care | 6 | 26% | | Health Diagnostics | 4 | 17% | | Biopharma | 3 | 13% | | Pharmaceutical | 3 | 13% | 13 industries tracked in total. ### Stage | Stage | Investments | Share | | --- | --- | --- | | Series B | 7 | 30% | | Series A | 3 | 13% | | Series C | 2 | 9% | | Series D | 1 | 4% | | Post-IPO Equity | 1 | 4% | ### Country | Country | Investments | Share | | --- | --- | --- | | China | 7 | 30% | | United States | 3 | 13% | | Singapore | 1 | 4% | ## Investments | Company | Description | Amount | Stage | Date | Website | | --- | --- | --- | --- | --- | --- | | Scivita Medical Technology | Scivita Medical is a high-tech enterprise engaged in the field of optical diagnosis and treatment, multidimensional images development, high-performance materials research and precision manufacturing with minimally invasive medical treatment. Scivita Medical's product covers both flexible endoscopy and rigid endoscopy, and has uniqueadvantages in the research and commercialization of all cutting-edge technologies in the field of medical endoscopes. It has ultra-high-definition visualization technology (such as 4K UHD visualization), 3D visualization technology, special light visualization technology (such as fluorescence visualization), ultra-fine endoscopic visualization technology, single-use technology, etc. | $61.9M | Series B | Aug 05, 2021 | | | Scivita Medical Technology | Scivita Medical is a high-tech enterprise engaged in the field of optical diagnosis and treatment, multidimensional images development, high-performance materials research and precision manufacturing with minimally invasive medical treatment. Scivita Medical's product covers both flexible endoscopy and rigid endoscopy, and has uniqueadvantages in the research and commercialization of all cutting-edge technologies in the field of medical endoscopes. It has ultra-high-definition visualization technology (such as 4K UHD visualization), 3D visualization technology, special light visualization technology (such as fluorescence visualization), ultra-fine endoscopic visualization technology, single-use technology, etc. | $61.9M | Series B | Aug 05, 2021 | | | Pulse | Pulse is a health care service provider that assess coronary physiology and biomechanics through innovative techniques. | $100M | Series C | Aug 02, 2021 | | | Scivita Medical Technology | Scivita Medical is a high-tech enterprise engaged in the field of optical diagnosis and treatment, multidimensional images development, high-performance materials research and precision manufacturing with minimally invasive medical treatment. Scivita Medical's product covers both flexible endoscopy and rigid endoscopy, and has uniqueadvantages in the research and commercialization of all cutting-edge technologies in the field of medical endoscopes. It has ultra-high-definition visualization technology (such as 4K UHD visualization), 3D visualization technology, special light visualization technology (such as fluorescence visualization), ultra-fine endoscopic visualization technology, single-use technology, etc. | $61.7M | Series A | Apr 26, 2021 | | | Scivita Medical Technology | Scivita Medical is a high-tech enterprise engaged in the field of optical diagnosis and treatment, multidimensional images development, high-performance materials research and precision manufacturing with minimally invasive medical treatment. Scivita Medical's product covers both flexible endoscopy and rigid endoscopy, and has uniqueadvantages in the research and commercialization of all cutting-edge technologies in the field of medical endoscopes. It has ultra-high-definition visualization technology (such as 4K UHD visualization), 3D visualization technology, special light visualization technology (such as fluorescence visualization), ultra-fine endoscopic visualization technology, single-use technology, etc. | $61.7M | Series A | Apr 26, 2021 | | | Cryofocus Biotech | Cryofocus Biotech is a Shanghai-based cryoablation device manufacturer, focusing on the application of cryogenic technology in the field of cardiovascular interventional therapy. | | Series B | Feb 22, 2021 | | | Xingxing Charging | Xingxing Charging provides safe and intelligent charging services. | | Series B | Jan 01, 2021 | | | Yingsheng Biology | Yingsheng Biotechnology Co., Ltd. (referred to as Yingsheng Bio) was established in 2009, and is committed to the application of molecular diagnostic techniques such as maternal and child health, neonatal genetic diseases, metabolic diseases, birth defects and other human genetics, and national eugenics engineering. Yingsheng's product lineincludes 45 innovative genetic metabolic disease screening reagents, 14 vitamins determination reagents, mass spectrometer automatic intelligent processing platform, and ultra-high performance liquid chromatography tandem mass spectrometry detection system. level. | | Series B | Nov 12, 2020 | | | HEMO BIOENGINEERING | HEMO BIOENGINEERING develops and provides innovative interventional medical devices to patients. | | Series B | Oct 19, 2020 | | | InventisBio | InventisBio is a biotech company whose product pipeline includes small molecule drug candidates for targeted therapies in lung cancer, breast cancer and gout. The company is also actively developing drugs that can be combined with other immune-oncology targeted therapies, such as PD-1 antibody, for various cancer indications. The company isco-founded by Dr. Yaolin Wang and other scientists who have previously worked at Merck and Schering-Plough, leading various drug discovery projects in oncology, metabolic and infectious disease areas. | $147M | Series D | Sep 27, 2020 | | 10 of 23 investments shown. ## Co-investors - [Hillhouse Investment](https://shizune.co/investors/profile/hillhouse-capital) — VC Fund, 8 deals together - [Lilly Asia Ventures](https://shizune.co/investors/profile/lilly-asia-ventures) — VC Fund, 8 deals together - [Hillhouse Investment](https://shizune.co/investors/profile/hillhouse-investment) — VC Fund, 6 deals together - [6 Dimensions Capital](https://shizune.co/investors/profile/6-dimensions-capital) — VC Fund, 4 deals together - [Inno-Chip](https://shizune.co/investors/profile/inno-chip) — VC Fund, 4 deals together - [Matrix Partners China](https://shizune.co/investors/profile/matrix-partners-china) — VC Fund, 4 deals together ## About Hillhouse Investment VC Fund · Singapore, Singapore Founded in 2005, Hillhouse is a leading global investment management firm, active across public equity, private equity, real estate and private credit. The firm invests over a long-term horizon and partners with exceptional entrepreneurs to deliver sustainable value creation for quality companies.Hillhouse is a full life-cycle private equityfirm, investing for the long term across opportunities in the healthcare, business services, consumer, and industrials sectors. The firm manages capital on behalf of global institutions such as non-profit foundations, endowments, and pensions. 5 contacts available at Hillhouse Investment. | Name | Title | Profile | | --- | --- | --- | | David Rhee | Partner | https://shizune.co/investors/profile/david-rhee | | Michael Yi | Partner | https://shizune.co/investors/profile/michael-yi | | Zhang Lei | Chairman, Founder, CEO | https://shizune.co/investors/profile/zhang-lei-2 | | Zhang Lei | Chairman, Founder, CEO | https://shizune.co/investors/profile/zhang-lei | | Ed Zhang | Venture Partner, HH Bioventure | https://shizune.co/investors/profile/ed-zhang-65b8 | ## Similar investors ### Similar stage - [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund - [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund - [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund ## FAQ ### What does Michael Yi invest in? Michael Yi invests primarily in Biotechnology, Health Care and Health Diagnostics startups, most often at Series B and Series A stage. Most of the 23 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio. ### When did Michael Yi last invest? The most recent investment recorded for Michael Yi closed in Aug 2021. Shizune tracks 23 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly. ### Is Shizune's investor data accurate? Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page. # About Shizune Shizune.co is an investor database. Core features: - 48,091 startup investors (angels, VCs, accelerators, and others) - Email, phone, LinkedIn (for intros), socials, and other contact data - Updated daily from public funding news - CSV and Excel export The User can access the full database FOR FREE after signing up: shizune.co